RecruitingPhase 2NCT07222579
Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)
Studying Mixed phenotype acute leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- West Virginia University
- Principal Investigator
- Ashkan Emadi, MDWVU Cancer Institute
- Intervention
- Subcutaneous Blinatumomab(drug)
- Enrollment
- 78 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2031
Study locations (1)
- West Virginia University Cancer Institute, Morgantown, West Virginia, United States
Collaborators
Amgen
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07222579 on ClinicalTrials.gov